Discovery of FDA-Approved Drugs as Inhibitors of Fatty Acid Binding Protein 4 Using Molecular Docking Screening

We first identified fluorescein,
ketazolam, antrafenine, darifenacin,
fosaprepitant, paliperidone, risperidone, pimozide, trovafloxacin,
and levofloxacin as inhibitors of fatty acid binding protein 4 using
molecular docking screening from FDA-approved drugs. Subsequently,
the biochemical characterizations showed that levofloxacin directly
inhibited FABP4 activity in both the in vitro ligand
displacement assay and cell-based function assay. Furthermore, levofloxacin
did not induce adipogenesis in adipocytes, which is the major adverse
effect of FABP4 inhibitors.